Novo Nordisk has pulled forward within the race to carry the primary oral GLP-1 for weight problems to market. The corporate introduced Friday that the FDA has accepted its New Drug Software (NDA) submission for a once-a-day 25mg capsule type of Wegovy (semaglutide) for power weight administration.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
